Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 1

Status

Recruiting 2Not yet recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 3OTHER_GOV 1INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 3Other solid neoplasm 1Breast 1

Conditions

Esophageal Squamous Cell Carcinoma 2Hepatic Artery Infusion 1Esophageal Neoplasms 1Advanced Solid Tumor 1

Interventions

pembrolizumab 1262Specimen Handling 924Magnetic Resonance Spectroscopy 829Carboplatin 821Cyclophosphamide 799Cisplatin 722Nivolumab 667Paclitaxel 627Radiotherapy 608Gemcitabine 570Biopsy 557Bevacizumab 478Dexamethasone 437fludarabine 407Docetaxel 377venetoclax 367Oxaliplatin 364Capecitabine 355Fluorouracil 355atezolizumab 350durvalumab 332Rituximab 329Drug Therapy 325Doxorubicin 316Radiosurgery 314Standard of Care 309Blood Specimen Collection 308Pemetrexed 304Ipilimumab 298Radiation 285

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
nedaplatin × 1 year × Clear all
NCT06953323 2026-03-27

A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors

Wigen Biomedicine Technology (Shanghai) Co., Ltd.

Phase 1/2 Recruiting
86 enrolled
Other solid neoplasm

Advanced Solid Tumor

NCT07374003 2026-01-28

Ipromlimab and Tuvonralimab Combined With Albumin-Bound Paclitaxel and Nedaplatin as Neoadjuvant Therapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma

Sun Yat-sen University

Phase 2 Active not recruiting
62 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT07284836 2025-12-16

Phase II Trial of Albumin-Bound Paclitaxel Combined With Nedaplatin (TP) Via Hepatic Arterial Infusion for Advanced Breast Cancer Patients With Liver Metastases After Failure of Standard Therapy

Zhejiang Cancer Hospital

Phase 2 Recruiting
30 enrolled
Breast

Hepatic Artery Infusion

NCT05880082 2025-08-24

PPIO-004-EC001

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

Phase 2 Completed
118 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT07046221 2025-07-20

Tislelizumab Combined With Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma Followed by CRT or Surgery

Fujian Cancer Hospital

Phase 2 Not yet recruiting
60 enrolled
Gastrointestinal

Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡